HNSP Intends to Acquire Two German Pharmaceutical Companies
2015-05-07 16:15
Source: China Securities Network
Summary: Hainan Shuangcheng Pharmaceuticals Co., Ltd. (HNSP) expressed that if this stock acquisition can be successfully consummated, it will help HNSP to continue its international growth strategy and expand its geographic footprint, which will help establish a good foundation for consolidating and increasing market share of HNSP’s main business.
On the evening of 06-May-2015, HNSP announced that the company has signed with two German natural persons a Letter of Intent to acquire 74.9% of the outstanding shares at an proposed transaction price of RMB 70 million to 200 million, respectively, in each of the two companies, owned by the latter, named Lyomark Pharma,
hereinafter referred to as Lyomark, and Bendalis GmbH, hereinafter referred to as Bendalis. HNSP company shares will resume trading tomorrow, May 7th, 2015.
Lyomark is a supplier of drug substances, drug products and R&D chemicals. Lyomark is specialized in niche proprietary and generic products and orphan drugs for rare diseases, presented as sterile injectable, lyophilized formulations in pre-filled syringes, vials and ampoules. By the end of 2014, the total assets of Lyomark stand at €6.60 million, with 2014 annual sales revenue of €7.60 million and 2014 net profit of €0.85 million.
Bendalis is a specialty pharmaceutical company focused on developing (in cooperation with third parties) and promoting high-barrier generic and niche proprietary oncology products in Germany and various international markets. As of the end of 2014, the total assets of Lyomark stood at €2.80 million, with 2014 annual sales revenue of €5.40 million and 2014 net profit of 00.20 million.
HNSP expressed that if this stock acquisition can be successfully consummated, it will help HNSP to continue its international growth strategy and expand its geographic footprint, which will help establish a good foundation for consolidating and increasing market share of HNSP’s main business.
Summary: Hainan Shuangcheng Pharmaceuticals Co., Ltd. (HNSP) expressed that if this stock acquisition can be successfully consummated, it will help HNSP to continue its international growth strategy and expand its geographic footprint, which will help establish a good foundation for consolidating and increasing market share of HNSP’s main business.
On the evening of 06-May-2015, HNSP announced that the company has signed with two German natural persons a Letter of Intent to acquire 74.9% of the outstanding shares at an proposed transaction price of RMB 70 million to 200 million, respectively, in each of the two companies, owned by the latter, named Lyomark Pharma,
hereinafter referred to as Lyomark, and Bendalis GmbH, hereinafter referred to as Bendalis. HNSP company shares will resume trading tomorrow, May 7th, 2015.
Lyomark is a supplier of drug substances, drug products and R&D chemicals. Lyomark is specialized in niche proprietary and generic products and orphan drugs for rare diseases, presented as sterile injectable, lyophilized formulations in pre-filled syringes, vials and ampoules. By the end of 2014, the total assets of Lyomark stand at €6.60 million, with 2014 annual sales revenue of €7.60 million and 2014 net profit of €0.85 million.
Bendalis is a specialty pharmaceutical company focused on developing (in cooperation with third parties) and promoting high-barrier generic and niche proprietary oncology products in Germany and various international markets. As of the end of 2014, the total assets of Lyomark stood at €2.80 million, with 2014 annual sales revenue of €5.40 million and 2014 net profit of 00.20 million.
HNSP expressed that if this stock acquisition can be successfully consummated, it will help HNSP to continue its international growth strategy and expand its geographic footprint, which will help establish a good foundation for consolidating and increasing market share of HNSP’s main business.
